| P50 | author | Vasishta S Tatapudi | Q58048160 |
| P2093 | author name string | Robert A Montgomery | |
| | Andrea A Zachary | |
| | Mary S Leffell | |
| P2860 | cites work | The virtual crossmatch--a screening tool for sensitized pediatric heart transplant recipients | Q82654389 |
| | Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies | Q83150706 |
| | First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells | Q84135263 |
| | Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies | Q84581805 |
| | Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients | Q84977614 |
| | Effect of Different Sensitization Events on HLA Alloimmunization in Kidney Transplantation Candidates | Q85281022 |
| | HLA-mismatched renal transplantation without maintenance immunosuppression | Q86746318 |
| | One kidney for life | Q87850651 |
| | Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients | Q89071408 |
| | Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study | Q89210051 |
| | Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium | Q22122334 |
| | Regulatory T-cell therapy in transplantation: moving to the clinic | Q27025869 |
| | Control of regulatory T cell development by the transcription factor Foxp3 | Q27860489 |
| | HLA Mismatching Strategies for Solid Organ Transplantation - A Balancing Act | Q28074462 |
| | Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 |
| | Effect of tolerance versus chronic immunosuppression protocols on the quality of life of kidney transplant recipients | Q33468225 |
| | Immunosuppressive strategies in transplantation | Q33591791 |
| | HLA-mismatched renal transplantation without maintenance immunosuppression | Q33640791 |
| | A Practical Review of C-Peptide Testing in Diabetes | Q33732640 |
| | Perception versus reality?: Virtual crossmatch--how to overcome some of the technical and logistic limitations | Q33888812 |
| | Domino paired kidney donation: a strategy to make best use of live non-directed donation | Q34552370 |
| | Messenger RNA for FOXP3 in the urine of renal-allograft recipients | Q34563002 |
| | Differences in immunogenicity of HLA antigens and the impact of cross-reactivity on the humoral response | Q34796926 |
| | Approaches to transplantation tolerance in humans | Q35743068 |
| | An update of the HLA genomic region, locus information and disease associations: 2004. | Q35951777 |
| | Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. | Q36189566 |
| | Allograft rejection mediated by memory T cells is resistant to regulation | Q36288969 |
| | HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease | Q36425417 |
| | Type 1 diabetes immunotherapy using polyclonal regulatory T cells | Q36509805 |
| | The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema | Q36568742 |
| | Genetics of autoimmune diseases--disorders of immune homeostasis | Q36670483 |
| | Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation | Q36722979 |
| | Clinical transplantation tolerance: many rivers to cross | Q36795236 |
| | Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors. | Q36827985 |
| | HLA-DQ Mismatches and Rejection in Kidney Transplant Recipients | Q36874597 |
| | Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. | Q36891917 |
| | HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide | Q37078261 |
| | The clinical utility of C-peptide measurement in the care of patients with diabetes | Q37108880 |
| | Clinical experience with mixed chimerism to induce transplantation tolerance | Q37309448 |
| | Review article: Luminex technology for HLA antibody detection in organ transplantation | Q37389868 |
| | Histocompatibility methods. | Q37418386 |
| | Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody | Q37575872 |
| | Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols | Q37685188 |
| | Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG. | Q37714099 |
| | An update on regulatory T cells in transplant tolerance and rejection. | Q37777645 |
| | Transplantation tolerance through mixed chimerism | Q37784380 |
| | The biology and medical implications of interleukin-6. | Q38207010 |
| | HLA-DR, DQ and DP typing using PCR amplification and immobilized probes | Q38336692 |
| | HLA epitopes as viewed by antibodies: what is it all about? | Q38364484 |
| | The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis | Q38393840 |
| | The Bacterial Enzyme IdeS Cleaves the IgG-Type of B Cell Receptor (BCR), Abolishes BCR-Mediated Cell Signaling, and Inhibits Memory B Cell Activation | Q38820671 |
| | Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients | Q38945149 |
| | Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells | Q39279238 |
| | 32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody | Q39630785 |
| | Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. | Q39716270 |
| | Renal transplantation between HLA identical siblings. Comparison with transplants from HLA semi-identical related donors | Q39808597 |
| | The Risk of Transplant Failure With HLA Mismatch in First Adult Kidney Allografts From Deceased Donors | Q39979362 |
| | IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation | Q40110030 |
| | Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 |
| | Tolerance and chimerism after renal and hematopoietic-cell transplantation | Q40428891 |
| | 100 HLA-identical sibling transplants. Prognostic factors other than histocompatibility | Q41015798 |
| | Center-defined unacceptable HLA antigens facilitate transplants for sensitized patients in a multi-center kidney exchange program | Q43472187 |
| | Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation | Q44002407 |
| | Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification | Q44919347 |
| | Differential effect of bortezomib on HLA class I and class II antibody | Q45184028 |
| | Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation | Q45627897 |
| | A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. | Q45932199 |
| | Calculated PRA: initial results show benefits for sensitized patients and a reduction in positive crossmatches | Q46083436 |
| | Complement-binding anti-HLA antibodies and kidney-allograft survival | Q46141053 |
| | Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation | Q46270876 |
| | Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production | Q46270888 |
| | Rituximab and intravenous immune globulin for desensitization during renal transplantation | Q46477840 |
| | A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients | Q46586216 |
| | Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation | Q46735702 |
| | Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment | Q46970385 |
| | HLA Diagnostics: Evaluating DSA Strength by Titration | Q47266425 |
| | Significance of the positive crossmatch test in kidney transplantation | Q47800073 |
| | Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection | Q47869308 |
| | Epitope analysis of HLA-DQ antigens: what does the antibody see? | Q48601896 |
| | Desensitization in HLA-incompatible kidney recipients and survival. | Q51018759 |
| | High-resolution, three-dimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes. | Q51540153 |
| | Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. | Q51563025 |
| | Kidney paired donation and optimizing the use of live donor organs. | Q51975686 |
| | Outcome of renal transplantation following a positive cross-match with historical sera: the ASHI survey. | Q52205098 |
| | IgG Degrading Enzyme of Streptococcus Pyogenes: An Exciting New Development in Desensitization Therapy. | Q52738922 |
| | A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. | Q52888768 |
| | Reply to "Allocation Based on Virtual Crossmatch Alone: Not Yet Ready for Primetime". | Q52983754 |
| | Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation. | Q53363804 |
| | Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. | Q53504304 |
| | Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. | Q54469292 |
| | "Hyperacute" renal-homograft rejection in man. | Q54626072 |
| | Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. | Q55034268 |
| | Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance | Q59074162 |
| | HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation | Q67522337 |
| | Characterization of lymphocytotoxic antibodies causing a positive crossmatch in renal transplantation. Relationship to primary and regraft outcome | Q69401035 |
| | Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment | Q69906820 |
| | Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells | Q70067993 |
| | Enzyme-linked immunoassay for anti-HLA antibodies--an alternative to panel studies by lymphocytotoxicity | Q70529151 |
| | Successful renal transplantation in patients with T-cell reactivity to donor | Q72539950 |
| | Clinical relevance of HLA-DPB locus matching for cadaver kidney retransplants: a report of the Collaborative Transplant Study | Q73353001 |
| | Improved graft survival after renal transplantation in the United States, 1988 to 1996 | Q73502580 |
| | Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial | Q79364646 |
| | Pretransplant risk assessment in renal allograft recipients using virtual crossmatching | Q79921631 |
| | Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility | Q80318190 |
| | CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates | Q80444346 |
| | Transplanting patients with a positive donor-specific crossmatch: a single center's perspective | Q81143143 |
| | Detection of antibodies to HLA-DP in renal transplant recipients using single antigen beads | Q81600356 |
| P433 | issue | 9 | |
| P304 | page(s) | 558-570 | |
| P577 | publication date | 2018-09-01 | |
| P1433 | published in | Nature Reviews Nephrology | Q2079275 |
| P1476 | title | HLA in transplantation | |
| P478 | volume | 14 | |